X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1458) 1458
Publication (286) 286
Newsletter (19) 19
Book Chapter (5) 5
Book Review (5) 5
Conference Proceeding (4) 4
Magazine Article (3) 3
Newspaper Article (3) 3
Dissertation (2) 2
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (1263) 1263
humans (1150) 1150
index medicus (1057) 1057
protein kinase inhibitors - pharmacology (609) 609
pyrimidines - pharmacology (597) 597
oncology (562) 562
animals (469) 469
thiazoles - pharmacology (466) 466
cell line, tumor (398) 398
imatinib (376) 376
antineoplastic agents - pharmacology (369) 369
imatinib mesylate (340) 340
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (327) 327
pharmacology & pharmacy (321) 321
female (319) 319
chronic myeloid-leukemia (309) 309
mice (301) 301
cancer (291) 291
male (281) 281
chronic myelogenous leukemia (270) 270
pyrimidines - therapeutic use (262) 262
chronic myeloid leukemia (259) 259
protein kinase inhibitors - therapeutic use (259) 259
hematology (249) 249
nilotinib (241) 241
antineoplastic agents - therapeutic use (224) 224
benzamides (221) 221
leukemia (211) 211
hemic and lymphatic diseases (201) 201
piperazines - pharmacology (201) 201
research (197) 197
cell proliferation - drug effects (195) 195
dasatinib - pharmacology (194) 194
protein-tyrosine kinases - antagonists & inhibitors (194) 194
thiazoles - therapeutic use (193) 193
apoptosis - drug effects (191) 191
bcr-abl (191) 191
mutation (191) 191
src-family kinases - antagonists & inhibitors (184) 184
drug resistance, neoplasm (178) 178
article (176) 176
middle aged (173) 173
phosphorylation (173) 173
resistance (171) 171
tyrosine (171) 171
activation (169) 169
kinases (169) 169
src-family kinases - metabolism (168) 168
signal transduction - drug effects (166) 166
apoptosis (165) 165
tyrosine kinase inhibitor (160) 160
drug therapy (158) 158
tyrosine kinase (154) 154
adult (152) 152
aged (144) 144
expression (141) 141
analysis (139) 139
src (130) 130
tyrosine kinase inhibitors (128) 128
fusion proteins, bcr-abl - genetics (125) 125
in-vitro (125) 125
care and treatment (124) 124
therapy (122) 122
piperazines - therapeutic use (119) 119
cell biology (117) 117
dose-response relationship, drug (117) 117
signal transduction (115) 115
fusion proteins, bcr-abl - antagonists & inhibitors (111) 111
leukemia, myelogenous, chronic, bcr-abl positive - genetics (111) 111
drug synergism (108) 108
kinase inhibitor (107) 107
chemotherapy (105) 105
leukemia, myelogenous, chronic, bcr-abl positive - pathology (104) 104
biochemistry & molecular biology (102) 102
health aspects (102) 102
dosage and administration (101) 101
antineoplastic agents (98) 98
xenograft model antitumor assays (98) 98
pyrimidines - administration & dosage (97) 97
treatment outcome (97) 97
proteins (92) 92
protein kinase inhibitors - administration & dosage (90) 90
cells (89) 89
genetic aspects (89) 89
pyrimidines - adverse effects (89) 89
drug resistance (88) 88
drug resistance, neoplasm - genetics (87) 87
phosphorylation - drug effects (87) 87
cell survival - drug effects (86) 86
fusion proteins, bcr-abl - metabolism (84) 84
inhibitors (84) 84
k562 cells (83) 83
antimitotic agents (82) 82
c-src (82) 82
cml (82) 82
medicine & public health (81) 81
thiazoles - administration & dosage (81) 81
drug resistance, neoplasm - drug effects (80) 80
tumors (80) 80
chronic-phase (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1472) 1472
Japanese (12) 12
Chinese (8) 8
German (3) 3
Russian (2) 2
Spanish (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 22, pp. 1665 - 1675
Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These... 
GROWTH-FACTOR RECEPTOR | CONTROLLED-TRIAL | ANTIANGIOGENIC THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | BONE METASTASES | C-MET | SIPULEUCEL-T APC8015 | ABIRATERONE ACETATE | TUMOR MICROENVIRONMENT | ANGIOGENESIS INHIBITION | Cancer Vaccines - pharmacology | Humans | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Prostatic Neoplasms - immunology | RANK Ligand - pharmacology | Receptors, Androgen - drug effects | Treatment Failure | Prostatic Neoplasms - drug therapy | Phenylthiohydantoin - pharmacology | Tumor Microenvironment - drug effects | Dasatinib | Antibodies, Monoclonal - pharmacology | Angiogenesis Inhibitors - pharmacology | Clusterin - pharmacology | Pyrimidines - pharmacology | Denosumab | Prostate-Specific Antigen - blood | Orchiectomy | Signal Transduction - drug effects | Anilides - pharmacology | Mice | Receptor Cross-Talk - drug effects | Endothelin-1 - antagonists & inhibitors | Immunotherapy - methods | Taxoids - pharmacology | Ipilimumab | Tissue Extracts - pharmacology | Bone Remodeling - drug effects | Pyrrolidines - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Mice, SCID | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Xenograft Model Antitumor Assays | Cancer Vaccines - immunology | Pyrroles - pharmacology | Animals | RANK Ligand - antagonists & inhibitors | Pyridines - pharmacology | Thiazoles - pharmacology | Immune response | Development and progression | Cellular signal transduction | Research | Drug therapy | Health aspects | Prostate cancer | Risk factors | Review
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 03/2013, Volume 24, Issue 3, pp. 251 - 259
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2015, Volume 172, Issue 15, pp. 3805 - 3816
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Cell culture | Values | Cell division | Cytotoxicity | Regression analysis | Kinases | Cancer therapies | Cell growth | Cell cycle | Software | Mutation | Drug dosages | Methods | Tumors | Apoptosis | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 2017, Volume 117, Issue 12, pp. 1777 - 1786
Background: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and... 
Nuclear internalisation | Acquired resistance | IGF-1R | Colorectal cancer | BRAF mutation | colorectal cancer | I RECEPTOR | TUMOR-CELLS | COMBINATION | acquired resistance | INSULIN | nuclear internalisation | MUTATION STATUS | ONCOLOGY | POOR-PROGNOSIS | KRAS | INHIBITOR | TRANSCRIPTION FACTOR | EXPRESSION | Leucovorin - administration & dosage | Receptor, IGF Type 1 - metabolism | Molecular Chaperones - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Panitumumab | Drug Resistance, Neoplasm | Male | Protein Inhibitors of Activated STAT - metabolism | Protein Transport - drug effects | Cell Nucleus - metabolism | Colorectal Neoplasms - drug therapy | Protein Inhibitors of Activated STAT - genetics | Camptothecin - administration & dosage | Camptothecin - analogs & derivatives | Cell Survival - drug effects | Bevacizumab - administration & dosage | Antibodies, Monoclonal - pharmacology | HCT116 Cells | Curcumin - pharmacology | Molecular Chaperones - genetics | Pyrimidines - pharmacology | Dasatinib - pharmacology | Signal Transduction - drug effects | Sorafenib | Fluorouracil - pharmacology | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Molecular Targeted Therapy | Organoplatinum Compounds - pharmacology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Oxaliplatin | Female | Antineoplastic Agents - pharmacology | Gene Silencing | Fatty Acids, Unsaturated - pharmacology | HT29 Cells | Pyrroles - pharmacology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cetuximab - administration & dosage | Aged | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Colorectal Neoplasms - pathology | Immunohistochemistry | Medical research | Cell survival | Insulin-like growth factor I | RNA-mediated interference | Colorectal carcinoma | Chemoresistance | Clinical trials | Insulin-like growth factors | Metastasis | Insulin | Patients | Survival | Metastases | Proteins | SUMO protein | Chemotherapy | Cell lines | Monoclonal antibodies | Tumors | Cancer | Translational Therapeutics
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5745 - 5755
Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however,... 
EFFICACY | ONCOLOGY | SAFETY | SUNITINIB | C-KIT | MYELOID-LEUKEMIA | MECHANISMS | MUTATIONS | DASATINIB | IMATINIB RESISTANCE | NILOTINIB | Exons | Humans | Molecular Conformation | Imidazoles - chemistry | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Pyridazines - pharmacology | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Gastrointestinal Stromal Tumors - diagnosis | Gastrointestinal Stromal Tumors - pathology | Inhibitory Concentration 50 | Female | Indoles - pharmacology | Proto-Oncogene Proteins c-kit - genetics | Tumor Burden - genetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Imidazoles - therapeutic use | Gastrointestinal Stromal Tumors - genetics | Pyridazines - therapeutic use | Disease Models, Animal | Neoplasm Recurrence, Local | Models, Molecular | Imidazoles - pharmacology | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Imatinib Mesylate | Piperazines - pharmacology | Pyridazines - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Pyrroles - pharmacology | Animals | Tumor Burden - drug effects | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Protein Kinase Inhibitors - pharmacology | Mutation | Proto-Oncogene Proteins c-kit - chemistry | Index Medicus | GIST | ponatinib | tyrosine kinase inhibitor | resistance | KIT
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 12/2014, Volume 171, Issue 24, pp. 5757 - 5773
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 10/2009, Volume 158, Issue 4, pp. 1153 - 1164
Background and purpose:  ABC multidrug transporters (MDR-ABC proteins) cause multiple drug resistance in cancer and may be involved in the decreased... 
ADME-Tox | CML | TKI | ABCB1 | Bcr-Abl | MDR | ABCG2 | ADME‐Tox | Bcr‐Abl | CHRONIC MYELOGENOUS LEUKEMIA | MULTIDRUG TRANSPORTER | DRUG-RESISTANCE | CHRONIC MYELOID-LEUKEMIA | P-GLYCOPROTEIN | TYROSINE KINASE INHIBITORS | HIGH-AFFINITY INTERACTION | HEMATOPOIETIC STEM-CELLS | PHARMACOLOGY & PHARMACY | IMATINIB MESYLATE | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Thiazoles - metabolism | Nitriles - pharmacology | Aniline Compounds - metabolism | Protein-Tyrosine Kinases - metabolism | Drug Resistance, Multiple - drug effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Substrate Specificity | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Neoplasm Proteins - metabolism | Cyclosporins - pharmacology | Pyrimidines - metabolism | Quinolines - pharmacology | Dose-Response Relationship, Drug | ATP-Binding Cassette Transporters - metabolism | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Dasatinib | Nitriles - metabolism | Aniline Compounds - pharmacology | Pyrimidines - pharmacology | Neoplasms - drug therapy | Quinolines - metabolism | Pyrimidines - therapeutic use | K562 Cells | Cell Line, Tumor | ATP Binding Cassette Transporter, Sub-Family B | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Thiazoles - pharmacology | Aniline Compounds - therapeutic use | Fusion Proteins, bcr-abl - metabolism | ATP-Binding Cassette Transporters - antagonists & inhibitors | Nitriles - therapeutic use | Index Medicus | Research Papers
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 01/2014, Volume 15, Issue 1, pp. 3 - 9
Chemokines produced in distinct tissue microenvironments sustain migration of mature lymphocytes in lymphoglandula. Chemokine receptors expressed on chronic... 
microenvironment | targeted therapy | chemokines | chronic leukemia lymphoma | chemokines receptors | Chemokines receptors | Microenvironment | Targeted therapy | Chronic leukemia lymphoma | Chemokines | B-CELL RECEPTOR | SURVIVAL | ACTIVATION | PCI-32765 | PHASE-II | CXCR4 | IN-VITRO | ONCOLOGY | TYROSINE KINASE INHIBITOR | NODE MICROENVIRONMENT | GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Heterocyclic Compounds - pharmacology | Tumor Microenvironment | Antineoplastic Agents - therapeutic use | Thalidomide - pharmacology | Thiazoles - therapeutic use | Molecular Targeted Therapy | Thalidomide - analogs & derivatives | Antineoplastic Agents - pharmacology | Purines - therapeutic use | Quinazolinones - pharmacology | Oxazines - pharmacology | Pyridines - therapeutic use | Dasatinib | Purines - pharmacology | Receptors, CXCR4 - antagonists & inhibitors | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Clinical Trials as Topic | Pyrimidines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Receptors, CXCR4 - metabolism | Chemokine CXCL12 - metabolism | Oxazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Thiazoles - pharmacology | Heterocyclic Compounds - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Niacinamide - pharmacology | Quinazolinones - therapeutic use | Thalidomide - therapeutic use | Review
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis
Journal Article
Leukemia, ISSN 0887-6924, 03/2015, Volume 29, Issue 3, pp. 586 - 597
Mutations in the BCR-ABL1 kinase domain are an established mechanism of tyrosine kinase inhibitor (TKI) resistance in Philadelphia chromosome-positive... 
TYROSINE KINASE INHIBITORS | PROGENITOR CELLS | EXCHANGE MASS-SPECTROMETRY | STEM-CELLS | CHRONIC-PHASE | ONCOLOGY | IMATINIB | HEMATOLOGY | LYN KINASE | CANCER-THERAPY | SMALL-MOLECULE INHIBITOR | SIGNAL TRANSDUCER | Leukocytes, Mononuclear - metabolism | Small Molecule Libraries - pharmacology | Phosphorylation | Luciferases - metabolism | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | STAT3 Transcription Factor - chemistry | Luciferases - genetics | Neoplastic Stem Cells - metabolism | Aminosalicylic Acids - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Neoplastic Stem Cells - pathology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Genes, Reporter | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Protein Structure, Tertiary | Dasatinib | Aminosalicylic Acids - pharmacology | Leukocytes, Mononuclear - drug effects | Signal Transduction | Sulfonamides - chemistry | Small Molecule Libraries - chemical synthesis | Gene Expression Regulation, Leukemic | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Drug Discovery | Imatinib Mesylate | Piperazines - pharmacology | Leukocytes, Mononuclear - pathology | Small Molecule Libraries - chemistry | Sulfonamides - chemical synthesis | Fusion Proteins, bcr-abl - genetics | Aminosalicylic Acids - chemical synthesis | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Molecular Docking Simulation | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | STAT3 Transcription Factor - antagonists & inhibitors | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Enzymes | Care and treatment | Genetic aspects | Regulation | Chronic myeloid leukemia | Drug resistance | Health aspects
Journal Article